What You Missed: Revolutionizing Biomarker Assessments in Alzheimer’s, Parkinson’s, ALS & MS
Discover, Validate & Integrate More Specific CNS Biomarkers to Improve Early Detection, Enhance Precision Neuroscience & Reduce the Translational Bottleneck
As the only industry-driven forum focused exclusively on biomarker discovery and validation for neurodegenerative and neuroinflammatory diseases, the 3rd Fluid & Imaging Biomarkers in Neuroscience Summit unites biotech, pharma and academic scientists to transform diagnosis and monitoring of Alzheimer’s, Parkinson’s, ALS, and MS.
50+ experts joined from Roche, Prothena, Eisai, Michael J. Fox Foundation and more to decode regulatory pathways, optimize IND timing, and harness breakthrough insights in p-tau217, alpha-synuclein, emerging omics platforms, and more.
As the field rapidly shifts toward blood-based diagnostics, high-sensitivity assays, and regulatory clarity, this is your unparalleled opportunity to collaborate with CNS biomarker leaders to shape a new wave of omics-based discoveries, surrogate endpoint success stories, pre-symptomatic detection technologies, and more.
It is a unique setting with some of the best and up and coming tools for drug development to be discussed and advanced.
FNIH
The speed networking was fun and useful for ice breaking. Panel discussions were informative.
Myrobalan Therapeutics
Industry News Round-Up: Why Biomarkers Are in the Spotlight
In just the past month, we’ve seen Roche achieve 91% plaque clearance with trontinemab and push its pTau217 blood test closer to routine adoption, Eisai expand real-world data for lecanemab while trialing new combination strategies, Eli Lilly secure EMA approval for donanemab, and the Michael J. Fox Foundation advance the first alpha-synuclein PET tracer into clinical testing. Each breakthrough underscores how rapidly fluid and imaging biomarkers are reshaping Alzheimer’s and Parkinson’s drug development, and why the conversations at this October’s 3rd Fluid & Imaging Biomarkers in Neuroscience Summit are so critical. With leaders from Roche, Eisai, Merck, Takeda, and the Michael J. Fox Foundation in the room, this is the one place to benchmark your strategy against the companies defining the future of biomarker-driven neurology.
Explore the Full 2025 Event Guide
- Get a full overview of the agenda, speakers, and sessions in one place
- Preview featured case studies that we’ll be shining a light on
- Discover exclusive content such as keynote highlights, attendee benefits and more
- Share easily with colleagues and decision-makers to mobilize interest
Official Partners
Attending Companies Include
Explore Related Events
Explore the 2025 Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.